Genetics of schizophrenia: From animal models to clinical studies

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 5, 2002, Pages 336-347

  Joober, Ridha ^a,c   Boksa, Patricia ^a   Benkelfat, Chawki ^a   Rouleau, Guy ^b  

^a Department of Psychiatry ^*  (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Genetic predisposition to disease; Genetics, behavioral; Mice; Models, animal; Phenotype; Receptors, serotonin; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR KINASE 2; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL MODEL; CONGENIC STRAIN; GENE IDENTIFICATION; GENETIC EPIDEMIOLOGY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN GENOME; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; PREPULSE INHIBITION; QUANTITATIVE TRAIT LOCUS; REVIEW; SCHIZOPHRENIA;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; SCHIZOPHRENIA; SEROTONIN;

EID: 0036758284     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 1993;50:527-40.
2. Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998;55:67-74.
3. Kety SS, Wender PH, Jacobsen B, Ingraham LJ, Jansson L, Faber B. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry 1994;51:442-55.
4. Rosenthal D, Wender PH, Kety SS, Welner J, Schulsinger F. The adopted-away offspring of schizophrenics. Am J Psychiatry 1971;128:307-11.
5. Gershon ES, Kelsoe JR, Kendler KS, Watson JD. A scientific opportunity [editorial]. Science 2001;294:957.
6. O'Rourke DH, Gottesman II, Suarez BK, Rice J, Reich T. Refutation of the general single-locus model for the etiology of schizophrenia. Am J Hum Genet 1982;34:630-49.
7. Risch N. Genetic linkage and complex diseases, with special reference to psychiatric disorders. Genet Epidemiol 1990;7:3-16.
8. Risch N, Merikangas KR. Linkage studies of psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 1993;243:143-9.
9. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990;46:222-8.
10. McGue M, Gottesman II, Rao DC. Resolving genetic models for the transmission of schizophrenia. Genet Epidemiol 1985;2:99-110.
11. Rao DC, Morton NE, Gottesman II, Lew R. Path analysis of qualitative data on pairs of relatives: Application to schizophrenia. Hum Hered 1981;31:325-33.
12. Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch Gen Psychiatry 1989;46:867-72.
13. Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F, et al. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nature Genet 1995;11:321-4.
14. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin J, et al. Schizophrenia: A genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 1995;60:252-60.
15. Kendler KS, Diehl SR. The genetics of schizophrenia: A current, genetic-epidemiologic perspective. Schizophr Bull 1993;19:261-85.
16. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000;288:678-82.
17. Hovatta I, Seppala J, Pekkarinen P, Tanskanen A, Lonnqvist J, Peltonen L. Linkage analysis in two schizophrenic families originating from a restricted subpopulation of Finland. Psychiatr Genet 1994;4:143-52.
18. Riley BP, McGuffin P. Linkage and associated studies of schizophrenia. Am J Med Genet 2000;97:23-44.
19. Turecki G, Rouleau GA, Joober R, Mari J, Morgan K. Schizophrenia and chromosome 6p. Am J Med Genet 1997;74:195-8.
20. Ichinose H, Nagatsu T. Molecular genetics of hereditary dystonia - Mutations in the GTP cyclohydrolase I gene. Brain Res Bull 1997;43:35-8.
21. Giasson BI, Lee VM. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001;31:885-8.
22. Gasser T. Molecular genetics of Parkinson's disease. Adv Neurol 2001;86:23-32.
23. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
24. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-9.
25. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomei, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94:2569-74.
26. 3 receptor gene in schizophrenia. Mol Psychiatry 1996;1:125-32.
27. 3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21:17-27.
28. 3 receptor gene and schizophrenia. Am J Med Genet 1997;74:40-3.
29. 3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47:6-16.
30. 3 receptor gene: Organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996;67:63-70.
31. Hawi Z, McCabe U, Straub RE, O'Neill A, Kendler KS, Walsh D, et al. Examination of new and reported data of the DRD3/MscI polymorphism: No support for the proposed association with schizophrenia. Mol Psychiatry 1998;3:150-5.
32. 3 receptor gene polymorphism and the psychiatric symptoms seen in first-break schizophrenic patients. Psychiatr Genet 1995;5:113-6.
33. 3 receptor gene and schizophrenia. Am J Med Genet 1995;60:558-62.
34. Macciardi F, Verga M, Kennedy JL, Petronis A, Bersani G, Pancheri PX, et al. An association study between schizophrenia and the dopamine receptor genes DRD3 and DRD4 using haplotype relative risk. Hum Hered 1994;44:328-36.
35. 3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998;3:72-5.
36. 3 receptor gene. Br J Psychiatry 1997;170:27-30.
37. 3 receptor gene. Hum Genet 1993;92:336-8.
38. 3 receptor Gly9/Ser9 polymorphism and schizophrenia: No increased frequency of homozygosity in German familial cases. Schizophr Res 1996;20:181-6.
39. 3 receptor gene-expressed variant and schizophrenia. Am J Med Genet 1996;67:232-4.
40. 3 receptor gene and schizophrenia. Am J Psychiatry 1994;151:107-11.
41. Spurlock G, Williams J, McGuffin P, Aschauer HN, Lenzinger E, Fuchs K, et al. European Multicentre Association Study of Schizophrenia: A study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. Am J Med Genet 1998;81:24-8.
42. 3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-45.
43. 3 receptor gene polymorphism. Am J Med Genet 1996;67:366-8.
44. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-5.
45. 2A receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia [letter]. Lancet 1997;349:1221.
46. 2A receptor T102C polymorphism and schizophrenia. Lancet 1996; 347:1831-2.
47. 2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996;153:1092-4.
48. 2A receptor gene. Lancet 1995;346:281-2.
49. 2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-6.
50. 2A gene and schizophrenia: Relation to phenotype and drug response variability. J Psychiatry Neurosci 1999;24:141-6.
51. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
52. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7.
53. Schork NJ, Cardon LR, Xu X. The future of genetic epidemiology. Trends Genet 1998;14:266-72.
54. Sullivan PF, Eaves LJ, Kendler KS, Neale MC. Genetic case-control association studies m neuropsychiatry. Arch Gen Psychiatry 2001;58:1015-24.
55. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
56. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291:1304-51.
57. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33.
58. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52: 506-16.
59. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
60. Cadenhead KS, Geyer MA, Braff DL. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am J Psychiatry 1993;150:1862-7.
61. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits. Am J Psychiatry 2000;157:1660-8.
62. Ekelund J, Hovatta I, Parker A, Paunio T, Varilo T, Martin R, et al. Chromosome 1 loci in Finnish schizophrenia families. Hum Mol Genet 2001;10:1611-7.
63. Tecott LH, Wehner JM. Mouse molecular genetic technologies, promise for psychiatric research. Arch Gen Psychiatry 2001;58:995-1004.
64. Lynch M, Walsh B, editors. Principles of marker-based analysis. In: Genetics and Analysis of Quantitative Traits. 1st Ed. Sunderland (MA): Sinauer Associates, Inc.; 1998. p. 379-426.
65. Fortin A, Diez E, Rochefort D, Laroche L, Malo D, Rouleau GA, et al. Recombinant congenic strains derived from A/J and C57BL/6J: A tool for genetic dissection of complex traits. Genomics 2001;74:21-35.
66. Kramnik I, Demant P, Bloom BB. Susceptibility to tuberculosis as a complex genetic trait: Analysis using recombinant congenic strains of mice. Novartis Found Symp 1998;217:120-31.
67. van Wezel T, Ruivenkamp CA, Stassen AP, Moen CJ, Demant P. Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 1999;59:4216-8.
68. Fijneman RJ, van der Valk MA, Demant P. Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: Multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects. Exp Lung Res 1998;24:419-36.
69. Demant P, Lipoldova M, Svobodova M. Resistance to Leishmania major in mice [letter]. Science 1996;274:1392-3.
70. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: What we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000; 11:185-204.
71. Braff DL, Geyer MA. Habituation deficits, serotonergic function, and schizophrenia: New animal model data. Psychopharmacol Bull 1988;24:426-30.
72. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990; 47:181-8.
73. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987;13:643-68.
74. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 1990;25:485-98.
75. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 1998;24:285-301.
76. Yamada S. Disruption of prepulse inhibition of acoustic startle as an animal model for schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi 2000;20:131-9.
77. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-54.
78. Freedman R, Mirsky AF. Event-related potentials: Exogenous components. In: Steinhauer SR, Gruzelier JH, Zubin J, editors. Handbook of Schizophrenia. Vol. 5. Neuropsychology, Psychophysiology and Information Processing. Amsterdam: Elsevier; 1991. p. 71-90.
79. Braff DL, Stone C, Callaway E, Geyer M, Glick I, Bali L. Pre-stimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-43.
80. Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 1999;156:596-602.
81. Grillon C, Ameli R, Charney DS, Krystal J, Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 1992;32:939-43.
82. Kumari V, Soni W, Mathew VM, Sharma T. Prepulse inhibition of the startle response in men with schizophrenia: Effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiatry 2000;57:609-14.
83. Parwani A, Duncan EJ, Bartlett E, Madonick SH, Efferen TR, Rajan R, et al. Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol Psychiatry 2000;47:662-9.
84. Weike AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry 2000;47:61-70.
85. Perry W, Braff DL. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 1994;151:363-7.
86. Perry W, Geyer MA, Braff DL. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry 1999;56:277-81.
87. Butler RW, Jenkins MA, Geyer MA, Braff DL. Wisconsin card sorting deficit and deminished sensorimotor gating in discrete subgroup of schizophrenic patients. In: Taminga CA, Schultz SC, editors. Advnaces in Neuropsychiatry and Psychopharmacology: Schizophrenia Research. New York: Raven Press; 1991. p. 163-8.
88. Braff DL, Swerdlow NR, Geyer MA. Gating and habituation deficits in the schizophrenia disorders. Clin Neurosci 1995;3:131-9.
89. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 1993;33:298-301.
90. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: Preliminary results. Biol Psychiatry 1996;39:33-41.
91. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1995;58:192-200.
92. Joober R, Zarate JM, Rouleau G, Skamene E, Boksa P. Provisional mapping of quantitative trait loci modulating the acoustic startle response and prepulse inhibition of acoustic startle. Neuropsychopharmacology. 2002. In press.
93. Bassett AS, Chow EW. 22q11 deletion syndrome: A genetic subtype of schizophrenia. Biol Psychiatry 1999;46:882-91.
94. Li T, Ball D, Zhao J, Murray RM, Liu X, Sham PC, et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes: Application to a potential locus for schizophrenia at chromosome 22q11. Mol Psychiatry 2000;5:77-84.
95. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999;56:940-5.
96. Karayiorgou M, Gogos JA, Galke BL, Jeffery JA, Nestadt G, Wolyniec PS, et al. Genotype and phenotype analysis at the 22q11 schizophrenia susceptibility locus. Cold Spring Harb Symp Quant Biol 1996;61:835-43.
97. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995;92:7612-6.
98. Bakshi VP, Geyer MA. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience 1999;92:113-21.
99. Carasso BS, Bakshi VP, Geyer MA. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology 1998;37:401-4.
100. 2c-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 1998;18:3035-42.
101. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-22.
102. 108/158 Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 2002;59:662-3.
103. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996;22:431-45.
104. 3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects. Mol Psychiatry 2001;6:718-24.
105. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woemer M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-9.
106. Cuesta MJ, Peralta V, de Leon J. Schizophrenic syndromes associated with treatment response. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:87-99.
107. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychol Med 1992;22:347-52.
108. Keefe RS, Mohs RC, Davidson M, Losonczy MF, Silverman JM, Lesser JC, et al. Kraepelinian schizophrenia: A subgroup of schizophrenia? Psychopharmacol Bull 1988;24:56-61.
109. May PR, Van Putten T, Yale C. Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry 1980;137:1088-9.
110. Schultz SC, Conley RR, Kahn EM, Alexander J. Nonresponders to neuroleptics: A distinct subtype. In: Schultz C, Taminga CA, editors. Schizophrenia: Scientific Progress. New York, Oxford: Oxford University Press; 1989. p. 341-50.
111. Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Res 1992;42:129-44.
112. Itil TM, Shapiro D, Schneider SJ, Francis IB. Computerized EEG as a predictor of drug response in treatment-resistant schizophrenics. J Nerv Ment Dis 1981;169:629-37.
113. Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN. Computerized EEG: Predictor of outcome in schizophrenia. J Nerv Ment Dis 1975;160:118-203.
114. Lindstrom EM, Ohlund LS, Lindstrom LH, Ohman A. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients. Psychiatry Res 1992;42:145-58.
115. Duncun E, Wolkin A, Angrist B, et al. Plasma HVA in neuroleptic responsive and nonresponsive schizophrenics [poster]. American College of Neuropsychopharmacology Annual Meeting. San Juan, Puerto Rico; 1992.
116. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, et al. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 1994;51:132-8.
117. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma-free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 1991;30:475-82.
118. Brown W, Herz L. Neuroleptic response as a nosologic device. In: Tsuang M, Simpson JC, editors. Handbook of Schizophrenia. Vol. 3. Amesterdam: Elsevier; 1988. p. 139-49.
119. Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophr Bull 1989;15:123-9.
120. Friedman L, Knutson L, Shurell M, Meltzer HY. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 1991;29:865-77.
121. McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: Relationship to latency of neuroleptic response. Psychiatry Res 1991;37:97-103.
122. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C, et al. Dopamine blockade and clinical response: Evidence for two biological subgrops of schizophrenia. Am J Psychiatry 1989;146:905-8.
123. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med 1988; 18:873-85.
124. Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, et al. Familial schizophrenia and treatment response. Am J Psychiatry 1987;144:1271-6.
125. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997;42:34-43.
126. Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985;146:229-39.
127. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(Suppl 9):5-9.
128. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152:698-703.
129. Sautter F, McDermott B, Garver D. Familial differences between rapid neuroleptic response psychosis and delayed neuroleptic response psychosis. Biol Psychiatry 1993;33:15-21.
130. Kendler KS, Myers JM, O'Neill FA, Martin R, Murphy B, MacLean CJ, et al. Clinical features of schizophrenia and linkage to chromosomes 5q, 6p, 8p, and 10p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 2000; 157:402-8.
131. Joober R, Benkelfat C, Lal S, Palmour R, Bloom D, Labelle A, et al. Neuroleptic-resistant schizophrenia: Clinical, neuropsychological and family history characterization [abstract]. World Congress of Psychiatric Genetics. Cardiff, Scotland. Psychiatric Genet 1995;5(Suppl 1):S56.
132. Joober R, Rouleau GA, Lal S, Bloom D, Labelle A, Lalonde P, et al. Higher risk for schizophrenia in relatives of neuroleptic-non-responder schizophrenic patients [abstract]. Abstracts of the Biological Psychiatry Society Annual Meeting; 1999; Washington.
133. Joober R, Rouleau GA, Lal S, Dixon M, O'Driscoll G, Palmour R, et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 2002;53:229-38.
134. Joober R, Toulouse A, Benkelfat C, Lal S, Bloom D, Labelle A, et al. DRD3 and DAT1 genes in schizophrenia: A pharmacogenetic association study. J Psychiatr Res 2000;34:285-91.
135. Yamamato K, Cubells JF, Gelernter J, Benkelfat C, Lalonde P, Bloom D, et al. Dopamine beta-hydroxylase (DBH) gene and schizophrenia phenotypic variability: A genetic association study. Am J Med Genet 2000;96:528.
136. Joober R, Benkelfat C, Toulouse A, Lafreniere RG, Lal S, Ajroud S, et al. Analysis of 14 CAG repeat-containing genes in schizophrenia. Am J Med Genet 1999;88:694-9.
137. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, et al. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Mol Psychiatry 2000;5:323-6.
138. Farid M, Martinez ZA, Geyer MA, Swerdlow NR. Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences. Neuropsychopharmacology 2000;23:623-32.
139. 2 receptor blockade on the startle reflex and its prepulse inhibition in mice and rats of various strains. Ross Fiziol Zh Im I M Sechenova. 1999;85:857-64.
140. Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 1999;46:832-8.